1. Introduction to Poly (ADP-Ribose) Polymerase Inhibitors
1.1 PARP Inhibitors as Unique Cancer Therapy
1.2 Evolutionary Aspects of PARP Inhibitors
1.3 Prelude to PARP Proteins & their Inhibitors
2. PARP Proteins: An Attractive Target for Developing Cancer Therapeutics
2.1 Structural Organization of Target Site of PARP Inhibitors
2.2 Structural Organization of PARP Inhibitors
3. Therapeutic Exploitation of Role of PARP Proteins in Normal Cells & Cancer Cells
3.1 Significance of PARP Proteins in Normal Cells
3.2 Significance of PARP Proteins in Tumorigenesis: Affecting Cell Division & DNA Repair
3.3 PARP Inhibitors: Distinct Modes of Action for Eliminating Cancer Cells
4. Global Poly (ADP-Ribose) Polymerase Inhibitors Clinical Pipeline Overview
5. Commercially Available Poly (ADP-Ribose) Polymerase Inhibitors (PARP Inhibitors) as Cancer Monotherapy
5.1 Olaparib
5.1.1 Availability, Dosage & Treatment Schedule
5.1.2 Price Analaysis
5.2 Rucaparib
5.2.1 Availability, Dosage & Treatment Schedule
5.2.2 Price Analysis
5.3 Niraparib
5.3.1 Availability, Dosage & Treatment Schedule
5.3.2 Price Analysis
5.4 Promising PARP Inhibitors in Clinical Pipeline: Efficiency, Dosage & Expected Price
5.4.1 Talazoparib
5.4.2 Veliparib
6. Global PARP Inhibitor Cancer Therapy Current Market Scenario
6.1 PARP Inhibitor Market Outline
6.2 Market Segmentation by Patent
6.3 Market Segmentation by Drug Sales
6.4 Market Trends
7. PARP Inhibitors with Conventional Cancer Therapy: Efficacy, Dosage & Price Analysis
7.1 PARP Inhibitors with Chemotherapy
7.1.1 Temozolomide
7.1.2 Platinum Salts
7.1.3 Taxanes
7.1.4 Gemcitabine
7.1.5 Topoisomerase Inhibitors/Poisons
7.2 PARP Inhibitors in Combination with Radiotherapy
8. Improved Efficacy of PARP Inhibitors by Modern Cancer Therapies
8.1 Combination of PARP Inhibitors & Targeted Therapies
8.1.1 PARP Inhibitors with EGFR Inhibitors
8.1.2 PARP Inhibitors with VEGFR Inhibitors
8.1.3 PARP Inhibitors with PI3K/mTOR Inhibitors
8.1.4 PARP Inhibitors with Trastuzumab
8.1.5 Anti-endocrine agents
8.1.6 HSP90 Inhibitors
8.1.7 IGF-1R & HDAC Inhibitors
8.2 PARP Inhibitors in Combination with Immunotherapies
9. Factors Driving Global PARP Inhibitors Market
9.1 Consecutive Approvals of Several PARP Inhibitors & Anticipated Approvals in the Nearby Future
9.2 Strong clinical Pipeline
9.3 Large Patient Base
9.4 Commercial Success of Approved PARP Inhibitors
10. Global PARP Inhibitor Market Challenges
10.1 Scientific Limitations and the Number of Side Effects
10.2 Tedious approval process
11. Global PARP Inhibitors Market Future Forecast
11.1 PARP Inhibitors in the Pipeline: Shaping the Future of Ineffectively Treated Cancer
11.1.1 PARP Inhibitors for Prostate Cancer
11.1.2 PARP Inhibitors for Lung Cancer
11.1.3 PARP Inhibitors in Pancreatic Cancer
11.2 Market Opportunity
12. Global Cancer PARP Inhibitors Clinical Pipeline by Company, Indication & Phase
12.1 Preclinical
12.2 Clinical
12.3 Phase-I
12.4 Phase-I/II
12.5 Phase-II
12.6 Phase-III
13. Marketed Cancer PARP Inhibitors Clinical Insight by Company & Indication
13.1 Olaparib (Lynparza)
13.2 Niraparib (Zejula)
13.3 Rucaparib (Rubraca)
14. Competitive Landscape
14.1 2X Oncology
14.2 Abott Laboratories
14.3 Cephalon
14.4 Checkpoint Therapeutics
14.5 Eisai Co. Ltd
14.6 IMPACT Therapeutics
14.7 Jeil Pharmaceuticals
14.8 KuDOS Pharmaceuticals
14.9 Kyowa Hakko Kirin
14.10 Lead Therapeutics
14.11 Shanghai De Novo Pharmatech
Figure 1-2: Biochemistry & Biological Functions Of Poly ADP-Ribosylation Reaction Mediated by Poly (ADP-Ribose) Polymerase (PARP) Enzymes
Figure 2-1: Structural Organization of PARP-1 & PARP-2 Enzymes
Figure 3-1: PARP Proteins in DNA Damage Repair Mechanism
Figure 3-2: Importance of PARP in DNA Repair Mechanism in Normal Cells
Figure 3-3: Dual Action of PARP inhibition for Cancer Treatment
Figure 4-1: Global – Cancer PARP Inhibitors Pipeline by Phase (%), 2018 till 2023
Figure 4-2: Global – Cancer PARP Inhibitors Pipeline by Phase (Number), 2018 till 2023
Figure 4-3: Global – Cancer PARP Inhibitors Pipeline by Phase (%),2018 till 2023
Figure 4-4: Global – Cancer PARP Inhibitors Pipeline by Phase (Number), 2018 till 2023
Figure 5-1: Progression Free Survival in Patients with Platinum-Sensitive, Relapsed, BRCA-mutant Ovarian Cancer by Using a PARP Inhibitor for 30 Months
Figure 5-2: Olaparib - Available Concentrations (mg), 2018
Figure 5-3: Olaparib - Dosage Analysis (mg/Day)
Figure 5-4: Olaparib - 150mg & 100mg Tablet Dosage Analysis (mg/12 hour) By Tablet Concentration
Figure 5-5: Olaparib - 50mg Tablet Dosage Analysis (Number of Capsules/Day)
Figure 5-6: Olaparib - Price Analysis by Type (US$/Unit), 2018
Figure 5-7: Olaparib - Price Analysis by Type (US$/Packet), 2018
Figure 5-8: Olaparib - Average Price Analysis for Breast & Ovarian Cancer Treatment (US$), 2018
Figure 5-9: Olaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Reoccurent BRCA Mutated Population (US$), 2018
Figure 5-10: Olaparib - Total Cost Analysis for Ovarian Cancer Maintenance Therapy for Reoccurent BRCA Mutated Population (US$), 2018
Figure 5-11: Olaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Platinum Sensitive Germline BRCA Mutated Cancer Population (US$), 2018
Figure 5-12: Rucaparib - Available Concentrations of Drug (mg)
Figure 5-13: Rucaparib - Dosage Analysis (mg/Day), 2018
Figure 5-14: Rucaparib - 300mg & 200mg Tablet Dosage Analysis (mg/12 hour) By Tablet Concentration
Figure 5-15: Rucaparib - Price Analysis (US$), 2018
Figure 5-16: Rucaparib - Average Price Analysis for Reoccurent BRCA Mutated Cancer Treatment (US$), 2018
Figure 5-17: Rucaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Reoccurent BRCA Mutated Population (US$), 2018
Figure 5-18: Rucaparib - Total Cost Analysis for Maintenance Therapy for Reoccurent BRCA Mutated Cancer Population (US$), 2018
Figure 5-19: Niraparib - Dosage Analysis (mg/Day)
Figure 5-20: Niraparib - Price Analysis (US$), 2018
Figure 5-21: Niraparib - Average Price Analysis for Breast & Ovarian Cancer Treatment (US$), 2018
Figure 5-22: Niraparib - Maintenance Therapy Cost Analysis for Germline BRCA Mutated Cancer Population (US$), 2018
Figure 5-23: Niraparib - Maintenance Therapy Cost Analysis for Non - Germline BRCA Mutated Cancer Population (US$), 2018
Figure 5-24: Niraparib - Complete Cancer Treatment Cost Analysis
Figure 5-25: Talazoparib – Upcoming Concentration (mg), 2018
Figure 5-26: Talazoparib - Expected Price Analysis by Concentration (US$), 2018
Figure 5-27: Veliparib - Treatment Course Analysis indicated in Clinical Trials
Figure 5-28: Veliparib - Dosage Analysis indicated in Clinical Trials (mg)
Figure 5-29: Overall Survival in Patients with Breast Cancer Treated with Carboplatin + Paclitaxel with Veliparib v/s without Veliparib (Months)
Figure 6-1: Global – Lynparza (Olaparib) Patent Approval & Expiration Year by Drug Form, 2018
Figure 6-2: Lynparza (Olaparib) - Number of Granted Patents & Applications, 2018
Figure 6-3: US - Lynparza (Olaparib) Patent Analysis by Number, 2018
Figure 6-4: Global – Lynparza (Olaparib) Patent Analysis by Approved Drug Formulations, 2018
Figure 6-5: Global – Rubraca (Rucaparib) Patent Aprroval & Expiration Year, 2018
Figure 6-6: Rucaparib (Rubraca) - Number of Granted Patents & Applications, 2018
Figure 6-7: Global – Zejula (Niraparib) Patent Approval & Expiration Year, 2018
Figure 6-8: Zejula (Niraparib) - Granted Patents & Applications, 2018
Figure 6-9: Global – Lynparza (Olaparib) Sales (US$ Million), 2015-2017
Figure 6-10: Global – Rubraca (Rucaparib) Sales (US$ Milion), 2017
Figure 6-11: Global – Zejula (Niraparib) Sales (US$ Million), Q1’2017 & Q2’2017
Figure 6-12: Global – PARP Inhibitors End Users (Number of Patients/Year), 2018
Figure 7-1: Tolerable Dosage of Rucaparib & Temozolomide Combination Therapy in Clinical Trials for Advanced Malignancy (mg/m2)
Figure 7-2: Study of Veliparib + Temozolomide Showing Improved Survival of Patients with Metastatic Melanoma (Months)
Figure 7-3: Estimated Glioblastoma Treatment Cost for Temozolomide + PARP Inhibitor Therapy, (US$/Cycle)
Figure 7-4: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (mg/Day & mg/m2/Day)
Figure 7-5: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (Administeration/Cycle)
Figure 7-6: Olaparib & Paclitaxel Combination Therapy Cost Analysis for Metastatic Gastric Cancer (US$/Cycle)
Figure 7-7: Overall Survival of Patients with Metastatic Gastic Cancer with Paclitaxel Chemotherapy vs Combination Therapy with Olaparib (Months)
Figure 7-8: Overall Survival in Patients with Triple-Negative Breast Cancer Treated with Gemiciabine & Carboplatin Chemotherapy vs Combination Therapy with Iniparib (Months)
Figure 8-1: Overall Progression Free Survival in Patients with Recurrent Platinum-Sensitive High-Grade Serous or Endometrioid Ovarian Cancer Treated with Cediranib + Olaparib v/s Olaparib Monotherapy (Months), 2018
Figure 8-2: Olaparib & Cediranib Combination Therapy Dosage Analysis as per Clinical Trials (mg/Day)
Figure 9-1: Expected Approval of PARP Inhibitors in the Nearby Future
Figure 11-1: US - PARP Inhibitor Market Opprtunity in Ovarian Cancer by Patient Base Undergoing Treatment
Figure 11-2: US - PARP Inhibitor Market Opprtunity in Breast Cancer by Patient Base Undergoing Treatment
Table 11-1: Ongoing Clinical Trials of PARP Inhibitor Combination Therapy for Prostate Cancer
【免責事項】
https://www.marketreport.jp/reports-disclaimer